Adjunctive therapy in type 1 diabetes — compounds assessed

§4Compounds assessed

Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.

• Liraglutide in type 1 diabetes (adjunct)

  GLP-1 receptor agonist (acylated, once-daily)2 contributing trialsfull monograph

  HbA1c reduction of approximately 0.2 % with increased hypoglycaemia and hyperketonaemia — The Institute records this as a programme in which a statistically detectable benefit was judged not to justify the safety signal, and no approval followed.

  Moderate
• Pramlintide in type 1 diabetes (adjunct)

  Amylin analogue, short-acting1 contributing trialfull monograph

  HbA1c reduction of approximately 0.3 % with weight reduction of 1.4 kg and reduced insulin requirement — The only amylin analogue with an approved indication as an insulin adjunct. Modest glycaemic effect with a meaningful severe-hypoglycaemia signal at…

  Moderate

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015;373(1):11–22. doi:10.1056/NEJMoa1411892 · PMID 26132939

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.